Lachmann Nils, Schütz Manuela, Budde Klemens, Schönemann Constanze, Waiser Johannes
Center for Tumor Medicine, HLA Laboratory, Charité- Universitätsmedizin Berlin, Berlin, Germany.
Clin Transpl. 2009:351-8.
These three case reports strongly support previously published data on the usefulness of bortezomib as an innovative and potent antihumoral rejection therapeutical. Contrary to the current, conventional therapeutic regimens including rituximab, PPH and IVIg the administration of bortezomib led to significantly decreased DSA levels facilitating prolonged allograft survival in two out of three cases. The present data might also suggest that the time point of first administration of bortezomib as therapeutic agent is of high importance for the outcome since progressed graft deterioration due to long persisting DSA cannot be reversed.
这三篇病例报告有力地支持了先前发表的关于硼替佐米作为一种创新且有效的抗体液排斥疗法的数据。与目前包括利妥昔单抗、血浆置换和静脉注射免疫球蛋白在内的传统治疗方案相反，硼替佐米的使用使三分之二的病例中供体特异性抗体（DSA）水平显著降低，有助于延长移植器官的存活时间。目前的数据还可能表明，作为治疗药物首次使用硼替佐米的时间点对治疗结果至关重要，因为长期存在的DSA导致的移植器官渐进性恶化无法逆转。
